

Case Docket No. GNE.2630P1C6 Date: February 11, 2002

Thereby certify that this correspondence and all marked attachments are being deposited with the

Washington, D.C. 20231, on

United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents.

February 11, 2002

(Date)

Ginger R. Dreger, Reg. No. 33,055

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Ashkenazi et al.

Appl. No.

09/978,193

Filed

October 15, 2001

For

SECRETED AND

TRANSMEMBRANE POLYEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Examiner

Unknown

Group Art Unit:

Unknown

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Dear Sir:

Enclosed for filing in the above-identified application is the following:

- (X) Amendment
- (X) Sequence Submission Statement in 429 pages;
- (X) Substitute Sequence Listing in computer readable form;
- (X) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;


The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410; and

(X) A return prepaid postcard.

Ginger R. Dreger

Registration No. 33,055

Attorney of Record



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspta.gov

APPLICATION NUMBER 09/978,193

FILING/RECEIPT DATE 10/15/2001

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

Avi J. Ashkenazi

P2630P1C6

CONFIRMATION NO. 4687 FORMALITIES LETTER

OC000000007180950

Ginger R. Dreger, Esq. Knobbe Martens Olson & Bear **Suite 1150** 201 California Street San Francisco, CA 94111

Date Mailed: 12/11/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Applicant ppl. No.

For

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MUS PATENT AND THE	
IN THE UNITED STATES PATENT AND 13) Group Art Unit Unknown
: Ashkenazi et al.) and also certify that this correspondence and all
: 09/978.193	hierosy examinents are being deposited or marked attachments are being deposited or united States Postal Service as first-class mail in an envelope addressed to: Patents, Washington, D.C. 20231, on
: October 15, 2001	February 11, 2002 (Date)
SECRETED AND TRANSMEMBRANE POLYEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME) Ginger R Dreger, Reg. No 33,055
. Unknown	

SEQUENCE SUBMISSION STATEMENT

Commissioner for Patents Washington, D.C. 20231

Examiner

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed December 11, 2001. Dear Sir: I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a) and included in the Substitute Sequence Listing submitted herewith, are supported in the application, and that the Substitute

I further state that the information recorded in the currently submitted substitute copy of the Sequence Listing does not include new matter. computer-readable form of the Sequence Listing is identical to the paper form of the Sequence Listing submitted herewith as required in 37 C.F.R. § 1.825(b).

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Februay 11, 2002

By:

Ginger R. Dreger Registration No. 33,055

Attorney of Record 620 Newport Center Drive, 16th Floor

Newport Beach, CA 92660

(415) 954-4114